A review of the challenge in measuring and standardizing BCR-ABL1

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Clinical Chemistry and Laboratory Medicine

• Publication date

  2017-08-28

• Fields of study

  Medicine

• Identifiers
  DOI 10.1515/cclm-2016-0927PMID 28222016
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Development and evaluation of a secondary reference panel for BCR-ABL1 quantification on the International Scale

  2016cited by this paper
• Performance criteria for reference measurement procedures and reference materials

  2015cited by this paper
• A longitudinal evaluation of performance of automated BCR-ABL1 quantitation using cartridge-based detection system

  2015cited by this paper
• Conversion, correction, and International Scale standardization: results From a Multicenter External Quality Assessment Study for BCR-ABL1 testing.

  2015cited by this paper
• Frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the European ENEST1st study

  2015cited by this paper
• Extreme PCR: efficient and specific DNA amplification in 15-60 seconds.

  2015cited by this paper
• Correlations between cytogenetic and molecular monitoring among patients with newly diagnosed chronic myeloid leukemia in chronic phase: post hoc analyses of the Rationale and Insight for Gleevec High-Dose Therapy study.

  2014cited by this paper
• Introduction to digital PCR.

  2014cited by this paper
• Calibration of BCR-ABL1 mRNA quantification methods using genetic reference materials is a valid strategy to report results on the international scale.

  2014cited by this paper
• Evaluation of clinical performance of the major BCR-ABL mRNA detection kit which enables conversion to international standard scale using the reference material calibrator.

  2014cited by this paper
• A certified plasmid reference material for the standardisation of BCR–ABL1 mRNA quantification by real-time quantitative PCR

  2014cited by this paper
• Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study IV.

  2014cited by this paper
• European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.

  2013cited by this paper
• Establishment and validation of analytical reference panels for the standardization of quantitative BCR-ABL1 measurements on the international scale.

  2013cited by this paper
• Fluorescence in situ hybridization patterns of BCR/ABL1 fusion in chronic myelogenous leukemia at diagnosis.

  2012cited by this paper
• Chitosan encapsulated quantum dots platform for leukemia detection.

  2012cited by this paper
• Sensitive quantitation of minimal residual disease in chronic myeloid leukemia using nanofluidic digital polymerase chain reaction assay

  2011cited by this paper
• Spinning disk platform for microfluidic digital polymerase chain reaction.

  2010cited by this paper
• Establishment of the first World Health Organization International Genetic Reference Panel for quantitation of BCR-ABL mRNA.

  2010cited by this paper
• The achievement of an early complete cytogenetic response is a major determinant for outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors.

  2010cited by this paper
• Obligatory Asymmetric Cell Division Regulates Self-Renewal In Hematopoietic Progenitor/Stem Cells

  2010cited by this paper
• NCCN clinical practice guidelines in oncology: chronic myelogenous leukemia.

  2009cited by this paper
• Standardisation of molecular monitoring for chronic myeloid leukaemia.

  2009cited by this paper
• Flow cytometric immunobead assay for the detection of BCR–ABL fusion proteins in leukemia patients

  2009cited by this paper
• High rates of durable response are achieved with imatinib after treatment with interferon α plus cytarabine: results from the International Randomized Study of Interferon and STI571 (IRIS) trial

  2009cited by this paper
• Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials.

  2008cited by this paper
• The use of Armored RNA as a multi-purpose internal control for RT-PCR

  2008cited by this paper
• molecule Beyond the increasing complexity of the immunomodulatory HLA-G

  2008cited by this paper
• Interlaboratory comparison of quantitative RT-PCR based detection for minimal residual disease in leukemias: a standardization approach in Japan.

  2008cited by this paper
• Finding of kinase domain mutations in patients with chronic phase chronic myeloid leukemia responding to imatinib may identify those at high risk of disease progression.

  2008cited by this paper
• Development of an integrated assay for detection of BCR-ABL RNA.

  2007cited by this paper
• Quantitative assessment of the BCR-ABL transcript using the Cepheid Xpert BCR-ABL Monitor assay.

  2007cited by this paper
• Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia.

  2006cited by this paper
• Molecular monitoring of chronic myelogenous leukemia: identification of the most suitable internal control gene for real-time quantification of BCR-ABL transcripts.

  2006cited by this paper
• Evaluation of real-time quantitative PCR machines for the monitoring of fusion gene transcripts using the Europe against cancer protocol

  2005cited by this paper
• Primer on medical genomics. Part XI: Visualizing human chromosomes.

  2004cited by this paper
• A nested RT-PCR assay to detect BCR/abl.

  2004cited by this paper
• Real-time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutations.

  2004cited by this paper
• Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia.

  2003cited by this paper
• Standardization and quality control studies of ‘real-time’ quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia – A Europe Against Cancer Program

  2003cited by this paper
• Quantitative real-time PCR: a powerful ally in cancer research.

  2003cited by this paper
• Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using ‘real-time’ quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR) – a Europe against cancer program

  2003cited by this paper
• Primer on medical genomics part II: Background principles and methods in molecular genetics.

  2002cited by this paper
• Chronic myelogenous leukemia.

  2002cited by this paper
• Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia.

  2002cited by this paper
• Interphase FISH studies of chronic myeloid leukemia.

  2002cited by this paper
• Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia.

  2002cited by this paper
• Tyrosine kinase inhibitors: From rational design to clinical trials

  2001cited by this paper
• A comparative analysis of FISH, RT-PCR, and cytogenetics for the diagnosis of bcr-abl-positive leukemias.

  1998cited by this paper
• Armored RNA Technology for Production of Ribonuclease-Resistant Viral RNA Controls and Standards

  1998cited by this paper
• The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype.

  1996cited by this paper
• Clinical significance of the BCR-ABL fusion gene in adult acute lymphoblastic leukemia: a Cancer and Leukemia Group B Study (8762).

  1992cited by this paper
• PRIMARY AMŒBIC MENINGOENCEPHALITIS AFTER SWIMMING IN STREAM WATER

  1973cited by this paper
• A New Consistent Chromosomal Abnormality in Chronic Myelogenous Leukaemia identified by Quinacrine Fluorescence and Giemsa Staining

  1973cited by this paper
• A rapid banding technique for human chromosomes.

  1971cited by this paper
• The minute chromosome (Phl) in chronic granulocytic leukemia.

  1962cited by this paper
• The minute chromosome (Ph1) in chronic granulocytic leukemia

  1962cited by this paper
• The minute chromosome (Phl) in chronic granulocytic leukemia.

  1962cited by this paper
• Clinical Trials and Observations

  year unknowncited by this paper

• The molecular management of classic myeloproliferative neoplasm

  2025cites this paper
• New practice of BCR::ABL1 standardization system based on p210 and p190 BCR::ABL1 reference materials.

  2024cites this paper
• Establishment of genomic RNA reference materials for BCR-ABL1 P210 measurement

  2024cites this paper
• Novel Dicarboximide BK124.1 Breaks Multidrug Resistance and Shows Anticancer Efficacy in Chronic Myeloid Leukemia Preclinical Models and Patients’ CD34+/CD38− Leukemia Stem Cells

  2022cites this paper
• Assessment of individual molecular response in chronic myeloid leukemia patients with atypical BCR-ABL1 fusion transcripts: recommendations by the EUTOS cooperative network

  2021cites this paper
• Impact of timely BCR-ABL1 monitoring before allogeneic stem cell transplantation among patients with BCR-ABL1-positive B-acute lymphoblastic leukemia

  2021cites this paper
• Extreme leukocytosis in a healthy young man and use of polymerase chain reaction for detection of BCR‑ABL

  2018cites this paper
• The Potential of Exosomes Derived from Chronic Myelogenous Leukaemia Cells as a Biomarker

  2018cites this paper
• How is the relationship between TWIST-1 and BCR-ABL1 gene expressions in chronic myeloid leukaemia patients?

  2018cites this paper
• differentiation therapy of myeloid leukemia reversing maturation arrest

  2017cites this paper
• P3 Fraction: Effect on HbA1c Values by HPLC.

  2016cites this paper